TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy.
Animals
Receptors, Immunologic
/ immunology
Mice
Gastrointestinal Microbiome
/ immunology
Membrane Glycoproteins
/ immunology
Immunotherapy
/ methods
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Macrophages
/ immunology
Mice, Inbred C57BL
Immune Checkpoint Inhibitors
/ pharmacology
Mice, Knockout
Female
Intestines
/ immunology
Journal
Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
17
5
2024
Statut:
ppublish
Résumé
The gut microbiota and tumor-associated macrophages (TAMs) affect tumor responses to anti-programmed cell death protein 1 (PD-1) immune checkpoint blockade. Reprogramming TAM by either blocking or deleting the macrophage receptor triggering receptor on myeloid cells 2 (TREM2) attenuates tumor growth, and lack of functional TREM2 enhances tumor elimination by anti-PD-1. Here, we found that anti-PD-1 treatment combined with TREM2 deficiency in mice induces proinflammatory programs in intestinal macrophages and a concomitant expansion of
Identifiants
pubmed: 38758808
doi: 10.1126/sciimmunol.adi5374
doi:
Substances chimiques
Trem2 protein, mouse
0
Pdcd1 protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM